Theravance Inc. (THRX): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Theravance ( THRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.4%. By the end of trading, Theravance rose $0.39 (1.1%) to $37.20 on light volume. Throughout the day, 312,791 shares of Theravance exchanged hands as compared to its average daily volume of 1,424,300 shares. The stock ranged in a price between $36.62-$37.62 after having opened the day at $36.68 as compared to the previous trading day's close of $36.81. Other companies within the Drugs industry that increased today were: NPS Pharmaceuticals ( NPSP), up 25.4%, Geron Corporation ( GERN), up 16.4%, Aastrom Biosciences ( ASTM), up 16.3% and GW Pharmaceuticals PLC ADR ( GWPH), up 16.0%.

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Theravance has a market cap of $4.0 billion and is part of the health care sector. Shares are up 65.5% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Theravance as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and disappointing return on equity.

On the negative front, Mast Therapeutics ( MSTX), down 41.8%, Tonix Pharmaceuticals ( TNXP), down 30.2%, Dendreon ( DNDN), down 26.1% and Genvec ( GNVC), down 23.2% , were all laggards within the drugs industry with Johnson & Johnson ( JNJ) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers